<DOC>
	<DOCNO>NCT00053157</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy radiation therapy . Giving sargramostim stem cell donor patient may reduce chance develop graft-versus-host disease follow stem cell transplantation . PURPOSE : Clinical trial study effectiveness sargramostim decrease graft-versus-host disease patient undergo donor stem cell transplantation hematologic cancer aplastic anemia .</brief_summary>
	<brief_title>Sargramostim Reducing Graft-Versus-Host Disease Patients Who Are Undergoing Donor Stem Cell Transplantation Hematologic Cancer Aplastic Anemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy sargramostim ( GM-CSF ) mobilize CD34+ hematopoietic stem cell donor reduce graft-vs-host disease patient allogeneic stem cell transplantation ( SCT ) hematologic malignancy aplastic anemia . - Determine safety GM-CSF allogeneic SCT transplantation patient . OUTLINE : This pilot study . - Donors : Donors receive sargramostim ( GM-CSF ) subcutaneously ( SC ) daily day 1-6 . Donors undergo stem cell harvest day 7 . Donors may undergo 3 apheresis procedure reach target stem cell dose may receive additional GM-CSF prior collection . - Patients : Patients receive condition therapy per transplantation protocol RP98-15 . Patients undergo allogeneic stem cell transplantation day 0 . Patients receive GM-CSF SC daily begin day 7 continue blood count recover . Patients follow weekly day 100 day 180 360 . PROJECTED ACCRUAL : A total 10 patient 10 donor accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignant hematologic disease , include : Acute chronic leukemia Myelodysplastic syndrome Myeloproliferative disorder Hodgkin 's lymphoma NonHodgkin 's lymphoma OR Aplastic anemia Planned transplantation RPCI IRBapproved allogeneic stem cell transplantation protocol HLAmatched ( 6/6 ) relate donor available PATIENT CHARACTERISTICS : Age 5 60 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient donor must use effective contraception No known allergy GMCSF No prior adverse reaction yeast recombinant molecule PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior allogeneic stem cell transplantation Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>childhood acute myeloid leukemia/other myeloid malignancy</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>